Edition:
United Kingdom

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

38.15USD
17 Aug 2018
Change (% chg)

$0.30 (+0.79%)
Prev Close
$37.85
Open
$37.70
Day's High
$38.40
Day's Low
$37.69
Volume
1,057,344
Avg. Vol
1,448,035
52-wk High
$47.81
52-wk Low
$29.53

Select another date:

Thu, Aug 16 2018

Photo

FDA approves Teva's generic of Mylan's EpiPen

The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs.

UPDATE 2-U.S. FDA approves Teva's generic of Mylan's EpiPen

Aug 16 The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs.

U.S. FDA approves first generic version of Mylan's EpiPen

Aug 16 The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's EpiPen for the emergency treatment of allergic reactions.

Mylan eyes 'all alternatives' as quarterly profit falls short

Mylan NV said on Wednesday its board had set up a committee to review possible strategic alternatives, citing a tough U.S. environment for generic drugmakers.

UPDATE 4-Mylan eyes 'all alternatives' as quarterly profit falls short

Aug 8 Mylan NV said on Wednesday its board had set up a committee to review possible strategic alternatives, citing a tough U.S. environment for generic drugmakers.

Drugmaker Mylan considering strategic alternatives

Aug 8 Drugmaker Mylan NV said on Wednesday it was evaluating a wide range of alternatives, sending its shares down nearly 5 percent before the bell.

Mylan signs U.S. license deal on Humira with AbbVie

AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

Mylan signs U.S. license deal on Humira with AbbVie

July 17 AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

Indivior warning on anti-opioid drug competition sends shares tumbling

British drugmaker Indivior warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.

BRIEF-Mylan Adds To Central Nervous System Portfolio With Launch Of Generic Exelon® Patch

* MYLAN ADDS TO CENTRAL NERVOUS SYSTEM PORTFOLIO WITH LAUNCH OF GENERIC EXELON® PATCH

Select another date: